Boston Therapeutics' sugardown(R) in Clinical Trials Reduces Glucose, Fructose and Insulin
December 29, 2015 08:53 ET
|
Boston Therapeutics
NEWTON, MA--(Marketwired - Dec 29, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) released final trial results from its proof of concept (POC) Sydney University study that showed consumption of...
Boston Therapeutics, Inc. Reports Third Quarter Results and Provides Corporate Update
November 20, 2015 16:57 ET
|
Boston Therapeutics
NEWTON, MA--(Marketwired - Nov 20, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of novel compounds based on complex carbohydrate chemistry for the treatment of metabolic...
Boston Therapeutics Completes Enrollment for BTI-320 Clinical Trial
October 06, 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Oct 6, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), completed enrollment...
Boston Therapeutics Pays Off Convertible Promissory Notes
September 29, 2015 13:48 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Sep 29, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) (the "Company") announced that on September 24, 2015, the Company paid in-full all of the Company's...
Boston Therapeutics' BTI-320 in Clinical Trial Significantly Reduces Both Glucose and Fructose Levels in Blood
September 15, 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Sep 15, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a...
Boston Therapeutics, Inc. Reports Second Quarter Results and Provides Corporate Update
August 13, 2015 15:18 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Aug 13, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of novel compounds based on complex carbohydrate chemistry for the treatment of diabetes...
Boston Therapeutics Nominates Philip Getter to Board of Directors
August 06, 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Aug 6, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
Boston Therapeutics' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point by Enrolling 30 Patients at the Chinese University of Hong Kong
July 08, 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Jul 8, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a...
Boston Therapeutics Presents Findings of BTI-320, a Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate as Therapy to Manage Blood Glucose at 75th Annual Meeting of the American Diabetes Association
June 08, 2015 06:18 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Jun 8, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and...
Boston Therapeutics & University at Buffalo's Translational Pharmacology Research Core Initiates BTI-320 Clinical Trials Alliance in Buffalo, NY and NYC's Chinatown
May 28, 2015 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 28, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) signed a Letter of Intent with Dr. Gene D. Morse, Director of the Translational Pharmacology Research...